Breast Cancer Health Center

Drug May Be New Option to Cut Breast Cancer Risk

Tracking Breast Cancer Risk continued...

The study wasn't able to show that the drug improved overall survival, however.

Adverse events were reported by 88% of women on Aromasin and 85% of women taking the placebo.

Arthritis and hot flashes were slightly more common in the treatment group.

There were no differences between the groups in the numbers of women who were newly diagnosed with osteoporosis or cardiovascular events.

Serious adverse events in the study were rare and none were judged to be attributable to Aromasin.

The study was sponsored by the Canadian Cancer Society Research Institute, the Canadian Institutes of Health Research, the Avon Foundation, and Pfizer, the company that makes Aromasin.